PBMC immunomodulated with interferon tau

PBMC immunomodulated with interferon tau refers to peripheral blood mononuclear cells (PBMCs) that have been exposed to or treated in vitro with interferon tau (IFNT), a type I interferon primarily secreted by the trophectoderm of ruminant conceptuses. This combination is used experimentally as an immunotherapy approach, particularly in reproductive medicine. Interferon tau modulates immune cell function and gene expression, promoting a uterine environment conducive to embryo implantation and pregnancy maintenance. PBMCs treated with IFNT can enhance endometrial receptivity by inducing the production of Th2 cytokines such as IL-4 and IL-10, stimulating progesterone production, and facilitating trophoblast invasion. The intrauterine administration of these immunomodulated PBMCs has been shown to improve pregnancy rates in patients experiencing repeated IVF failure[1]. The mechanism involves both direct effects on immune cells—such as inhibition of lymphocyte proliferation and stimulation of NK-like cell activity—and indirect effects on endometrial epithelial gene expression[1][3].

Other names

PBMCs stimulated with interferon tauperipheral blood mononuclear cells immunomodulated with IFNT